- Home
- SSSS vs XGN Comparison
SSSS vs XGN Comparison
Compare SSSS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- XGN
- Stock Information
- Founded
- SSSS 2010
- XGN 2002
- Country
- SSSS United States
- XGN United States
- Employees
- SSSS N/A
- XGN N/A
- Industry
- SSSS Finance: Consumer Services
- XGN Medical Specialities
- Sector
- SSSS Finance
- XGN Health Care
- Exchange
- SSSS Nasdaq
- XGN Nasdaq
- Market Cap
- SSSS 138.2M
- XGN 138.3M
- IPO Year
- SSSS N/A
- XGN 2019
- Fundamental
- Price
- SSSS $8.21
- XGN $6.99
- Analyst Decision
- SSSS Strong Buy
- XGN Strong Buy
- Analyst Count
- SSSS 3
- XGN 2
- Target Price
- SSSS $8.67
- XGN $7.50
- AVG Volume (30 Days)
- SSSS 369.3K
- XGN 228.1K
- Earning Date
- SSSS 08-06-2025
- XGN 08-04-2025
- Dividend Yield
- SSSS N/A
- XGN N/A
- EPS Growth
- SSSS N/A
- XGN N/A
- EPS
- SSSS N/A
- XGN N/A
- Revenue
- SSSS $3,644,430.00
- XGN $56,724,000.00
- Revenue This Year
- SSSS $5,400.03
- XGN $19.39
- Revenue Next Year
- SSSS N/A
- XGN $13.27
- P/E Ratio
- SSSS N/A
- XGN N/A
- Revenue Growth
- SSSS N/A
- XGN 1.78
- 52 Week Low
- SSSS $3.52
- XGN $1.71
- 52 Week High
- SSSS $8.77
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- SSSS 77.74
- XGN 52.04
- Support Level
- SSSS $7.26
- XGN $6.62
- Resistance Level
- SSSS $8.77
- XGN $7.38
- Average True Range (ATR)
- SSSS 0.30
- XGN 0.49
- MACD
- SSSS 0.03
- XGN -0.09
- Stochastic Oscillator
- SSSS 77.11
- XGN 28.89
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.